Nasic (Xylometazoline Hydrochloride)

Xylometazoline is a selective alpha‑adrenergic agonist. When sprayed into the nose it binds to α1‑ and α2‑adrenergic receptors on the blood vessels of the nasal mucosa, causing vasoconstriction. This reduces blood flow, decreases edema, and opens the nasal passages, providing rapid decongestion.

The appropriate dose of Nasic is determined by the prescribing healthcare professional. Typically, adults and children over the recommended age are instructed to spray one to two sprays into each nostril, not exceeding the maximum daily frequency. Exact dosing instructions should be followed on the product label or as advised by a clinician.

Safety data for Xylometazoline during pregnancy and lactation are limited. It is classified as a pregnancy category unknown, and use should only be considered if the potential benefit outweighs any possible risk. Pregnant or nursing women should consult their healthcare provider before using Nasic.

To place an order, visit the product page at gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasic’s active ingredient, Xylometazoline, is an alpha‑adrenergic agonist similar to oxymetazoline and phenylephrine. Compared with phenylephrine, Xylometazoline typically provides longer lasting relief with a lower incidence of systemic side effects. However, all topical decongestants share a risk of rebound congestion if used beyond the recommended duration.

Store Nasic at room temperature, preferably below 25 °C, in its original packaging. Protect the bottle from moisture, direct sunlight and extreme heat. Keep the spray tip clean and avoid contaminating the container. Do not freeze the product, and keep it out of reach of children.

Nasic is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator to deliver the recommended number of sprays. The same procedure is repeated in the other nostril if directed. Avoid sharing the spray device.

The most serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, and systemic cardiovascular effects such as elevated blood pressure, tachycardia, or arrhythmias, especially in patients with pre‑existing heart disease. Rarely, severe allergic reactions like anaphylaxis may occur. Discontinue use and seek medical attention if serious symptoms develop.

Nasic should not be used by individuals with known hypersensitivity to Xylometazoline or any other component of the formulation. It is also contraindicated in patients with severe hypertension, coronary artery disease, or those taking monoamine oxidase inhibitors. Children under the age specified on the label (often under 2 years) should not use the product unless directed by a physician.